CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B

Share this

CSL Behring to Acquire uniQure' Hemophilia B Candidate (AMT-061) for ~$2B


  • uniQure to receive $2B+ including $450M as up front in cash- $1.6B as regulatory & commercial milestones along with royalties in sales of  AMT-061 (etranacogene dezaparvovec) while CSL Behring to get an exclusive global right to commercialize AMT-061
  • uniQure will be responsible for the completion of the P-III HOPE-B study and scale-up manufacture for early commercial supply under an agreed plan with CSL Behring. uniQure will lead clinical development and regulatory activities- reimbursed by CSL Behring
  • The collaboration will foster CSL Behring’s gene therapy portfolio while allowing uniQure to expand and accelerate pipeline and platform. The AMT-061 consists of an AAV5 viral vector carrying a gene cassette with FIX-Padua- currently being evaluated in P-III study and could be one of the first gene therapies to provide long-term benefits to patients with hemophilia B

Click here- Click here to read full press release/ article | Ref: CSL Behring- Businesswire | Image: Norwood

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions